


EFFECTIVE DISCONTINUATION OF CONTINUOUS KIDNEY REPLACEMENT THERAPY IN ICU: THE EMERGING ROLE OF CELL CYCLE ARREST BIOMARKERS

Gregorio Romero-González^{a,b}, Yuanyuan Xie^{b,c}, Alejandra Molano-Triviño^b, Lilia Rizo-Topete^b, Fiorenza Ferrari^{b,d}, Silvia De Rosa^{b,e}, Alessandra Brendolan^{b,f}, Francesca Martino^{b,f}, Claudio Ronco^{b,f,g}

^aDepartment of Nephrology, Complejo Hospitalario de Navarra, Pamplona (Spain). ^bInternational Renal Research Institute of Vicenza (IRRIV), Vicenza (Italy). ^cDepartment of Nephrology, Molecular Cell Laboratory for Kidney Disease, Renji Hospital, School of Medicine, Shanghai Jiantong University, Shanghai (China). ^dDepartment of Intensive Care, I.R.C.C.S. Policlinico San Matteo, Pavia (Italy). ^eDepartment of Anesthesiology and Intensive Care, San Bortolo Hospital, Vicenza (Italy). ^fDepartment of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza (Italy). ^gDepartment of Medicine, University of Padova, Padova (Italy).



Conclusion: Urine output could be a significant factor related to effective discontinuation. However, the addition of cell cycle arrest biomarkers at the admission or discontinuation times can increase the likelihood of successful weaning from continuous kidney replacement therapy. Further studies are required to confirm our hypothesis.

38th Vicenza Course on AKI&CRRT
a week of virtual meetings

2-6 November 2020